Ongentys Shortage: What Providers and Prescribers Need to Know in 2026

As a prescriber managing patients with Parkinson's disease, you know that medication access directly impacts outcomes. Ongentys (Opicapone), the only once-daily COMT inhibitor available in the United States, has become an important tool for reducing off episodes in patients on Levodopa/Carbidopa therapy. But is it accessible to your patients when they need it?

This briefing covers the current supply situation, prescribing implications, cost and insurance landscape, and practical tools to help your patients access Ongentys in 2026.

Current Supply Status: No Formal Shortage

As of early 2026, Ongentys is not listed on the FDA's drug shortage database. Neurocrine Biosciences, which markets Ongentys in the U.S. under license from BIAL-Portela, continues to supply the medication through standard pharmaceutical distribution channels. The drug is available through retail pharmacies, specialty pharmacies, and mail-order services.

However, clinicians should be aware that patient-reported access difficulties are common — not due to supply disruption, but due to the dynamics of specialty medication distribution.

Timeline and Context

Understanding how Ongentys arrived at its current position helps contextualize the access challenges:

• April 2020: FDA approves Ongentys (Opicapone) 50 mg and 25 mg capsules for adjunctive treatment of off episodes in Parkinson's disease.
• June 2020: Neurocrine Biosciences launches Ongentys commercially in the U.S.
• 2020–2026: Gradual uptake as neurologists and movement disorder specialists adopt Ongentys into practice. No generic competition; no formal supply disruptions.
• March 2030: Earliest patent expiration date, after which generic Opicapone could potentially enter the market.

Prescribing Implications

When considering Ongentys for your patients, keep these clinical and practical factors in mind:

Clinical Advantages

• Once-daily dosing at bedtime — a significant adherence advantage over Entacapone, which must be taken with each Levodopa dose (up to 8 times daily).
• No hepatotoxicity monitoring required — unlike Tolcapone (Tasmar), which carries a boxed warning for fatal liver failure and requires regular liver function tests.
• Demonstrated efficacy: In pivotal trials (BIPARK-1 and BIPARK-2), Opicapone 50 mg significantly reduced absolute off time compared to placebo, with efficacy comparable to Entacapone.
• Once-daily COMT inhibition: Opicapone provides sustained COMT inhibition, maintaining levodopa bioavailability throughout the dosing interval.

Practical Considerations

• Empty stomach requirement: Patients must avoid food for 1 hour before and 1 hour after taking Ongentys. This is important to communicate clearly, as it can affect adherence if not well understood.
• Dyskinesia management: The most common adverse effect is dyskinesia, occurring in approximately 20% of patients in clinical trials. Providers should anticipate the potential need to adjust Levodopa doses when initiating Ongentys.
• Drug interactions: Ongentys is contraindicated with non-selective MAO inhibitors. Use caution with drugs metabolized by COMT (e.g., catecholamines). Selective MAO-B inhibitors can be used concomitantly. For a comprehensive review, see our drug interactions guide.

The Availability Picture

The primary access barriers your patients face are not supply-related but distribution-related:

Pharmacy Stocking

Most chain pharmacies (CVS, Walgreens, Rite Aid) do not routinely stock Ongentys due to low volume. Patients typically need to request that their pharmacy order it (1-2 business day turnaround) or find a pharmacy that already carries it.

Prior Authorization

The majority of commercial insurance plans and many Medicare Part D plans require prior authorization for Ongentys. Common PA criteria include:

• Confirmed diagnosis of Parkinson's disease
• Current use of Levodopa/Carbidopa
• Documentation of off episodes
• Some plans require trial and failure of Entacapone (step therapy)

Neurocrine Biosciences offers PA support through CoverMyMeds, which can streamline the submission process for your practice.

Cost Barrier

The retail price of Ongentys is approximately $645 to $1,003 per month without insurance. For commercially insured patients, the Ongentys Savings Program can reduce out-of-pocket costs to as low as $25 per fill. However, this program is not available to patients with government insurance (Medicare, Medicaid, Tricare).

Cost and Access Solutions

Here are the key resources to help your patients afford and access Ongentys:

• Ongentys Savings Program: $25 copay for eligible commercially insured patients. Details at ongentys.com/support.
• INBRACE Support Program: Neurocrine's comprehensive support offering, including dedicated Reimbursement and Patient Access Managers (RPAMs) who can work directly with your office on insurance navigation.
• CoverMyMeds: Electronic prior authorization tool integrated with many EHR systems. Reduces PA turnaround time.
• Discount coupons: GoodRx and SingleCare offer coupons bringing the cash price to $645-$758 for uninsured patients.
• Patient assistance programs: NeedyMeds and RxAssist maintain databases of manufacturer and independent assistance programs.

For a comprehensive overview of savings options to share with patients, see our article on saving money on Ongentys.

Tools and Resources for Your Practice

Medfinder for Providers offers a streamlined way to help patients locate pharmacies with Ongentys in stock. Rather than directing patients to call multiple pharmacies, you or your staff can search for nearby availability and provide patients with specific pharmacy options at the point of care.

Additional practice resources:

• Neurocrine HCP portal: ongentyshcp.com — prescribing information, dosing guides, and support program details.
• Formulary lookup tools: Verify coverage on specific insurance plans before prescribing.
• Pharmacy benefit managers (PBMs): For complex coverage situations, contacting the patient's PBM directly can expedite access.

Looking Ahead

Several developments may affect the Ongentys access landscape in the coming years:

• Generic entry (post-2030): The earliest patent expiration is March 2030. If generic Opicapone becomes available, it would likely reduce costs significantly and improve pharmacy stocking.
• Formulary evolution: As real-world evidence accumulates and the medication becomes more established, formulary placement and PA requirements may become more favorable.
• Pipeline treatments: Ongoing research into Parkinson's disease therapeutics may yield new adjunctive options, though no imminent competitors to Ongentys are expected in the near term.

Final Thoughts

Ongentys remains an effective and well-tolerated option for managing off episodes in Parkinson's disease. While it is not in a formal shortage, the realities of specialty medication distribution — limited pharmacy stocking, prior authorization requirements, and high cost — create practical barriers for patients.

As prescribers, proactive steps like using Medfinder for Providers, leveraging Neurocrine's support programs, and addressing insurance requirements early can significantly reduce your patients' access challenges. For a step-by-step guide, see our companion article: How to Help Your Patients Find Ongentys in Stock.